51
|
Abstract
Asthma and eczema (atopic dermatitis) are characterized by a number of unexplained phenomena: the familial aggregation of disease, the initiation of disease by apparently trivial exposure to allergens, the preferential transmission of disease from affected mothers and the large increase in prevalence of disease in Westernized societies in the last century. A number of genes and chromosomal regions have been identified that consistently show linkage to asthma and its related phenotypes. Known loci modify the strength of the atopic response, nonspecific inflammation, the ability to respond to particular allergens and nonspecific airway reactivity. Eczema has been shown to be due to a different set of genetic loci that are shared with other skin diseases such as psoriasis and leprosy. Genetic and genomic studies both provide evidence that epithelial surfaces are active in the induction of allergic disease.
Collapse
Affiliation(s)
- William Cookson
- University of Oxford, The Wellcome Trust Centre for Human Genetics, Oxford, England.
| |
Collapse
|
52
|
Williams CN, Kocher K, Lander ES, Daly MJ, Rioux JD. Using a genome-wide scan and meta-analysis to identify a novel IBD locus and confirm previously identified IBD loci. Inflamm Bowel Dis 2002; 8:375-81. [PMID: 12454612 DOI: 10.1097/00054725-200211000-00001] [Citation(s) in RCA: 42] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Abstract
Seven loci that potentially confer susceptibility to inflammatory bowel disease (IBD) or one of its subtypes have been identified to date; however, most are unconfirmed, and the complete set of loci contributing to disease susceptibility has not yet been determined. The authors aim to identify loci contributing to disease susceptibility in an IBD population from Canada and to compare their results in a systematic manner with those of previously published IBD data sets. The authors performed genome-wide linkage analysis on 63 IBD families from Nova Scotia, Canada. They then undertook a meta-analysis to combine the results of their study with those of the four previously published IBD genome-wide scans with complete data reported. Their genome-wide scan identified three regions of suggestive linkage to IBD: 11p, and The locus on chromosome 11p has not been previously reported. Meta-analysis of multiple scans revealed linked regions corresponding to the, and loci. Meta-analysis of linkage data is a powerful approach for identifying and confirming common susceptibility loci and specifically shows that, and are the major, common IBD susceptibility loci in the populations studied thus far.
Collapse
Affiliation(s)
- C Noel Williams
- Queen Elizabeth II Health Sciences Center University Hospital, Nova Scotia, Canada
| | | | | | | | | |
Collapse
|
53
|
Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, Dimitrijevic S, Mahon FX, Marin D, Nikolova Z, Olavarria E, Silberman S, Schultheis B, Cross NCP, Goldman JM. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002; 347:481-7. [PMID: 12181402 DOI: 10.1056/nejmoa020150] [Citation(s) in RCA: 448] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND A small proportion of patients with chronic myeloproliferative diseases have constitutive activation of the gene for platelet-derived growth factor receptor beta (PDGFRB), which encodes a receptor tyrosine kinase. The gene is located on chromosome 5q33, and the activation is usually caused by a t(5;12)(q33;p13) translocation associated with an ETV6-PDGFRB fusion gene. The tyrosine kinase inhibitor imatinib mesylate specifically inhibits ABL, PDGFR, and KIT kinases and has impressive clinical efficacy in BCR-ABL-positive chronic myeloid leukemia. METHODS We treated four patients who had chronic myeloproliferative diseases and chromosomal translocations involving 5q33 with imatinib mesylate (400 mg daily). Three of the four patients presented with leukocytosis and eosinophilia; their leukemia cells carried the ETV6-PDGFRB fusion gene. The fourth patient had leukocytosis, eosinophilia, and a t(5;12) translocation involving PDGFRB and an unknown partner gene; he also had extensive raised, ulcerated skin lesions that had been present for a long time. RESULTS In all four patients, a normal blood count was achieved within four weeks after treatment began. In the patient with skin disease, the lesions began to resolve shortly after treatment began. The t(5;12) translocation was undetectable by 12 weeks in three patients and by 36 weeks in the fourth patient. In the three patients with the ETV6-PDGFRB fusion gene, the transcript level decreased, and in one patient, it became undetectable by 36 weeks. All responses were durable at 9 to 12 months of follow-up. CONCLUSIONS Imatinib mesylate induces durable responses in patients with chronic myeloproliferative diseases associated with activation of PDGFRB.
Collapse
Affiliation(s)
- Jane F Apperley
- Department of Haematology, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, United Kingdom.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
54
|
Steer EJ, Cross NCP. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002; 107:113-22. [PMID: 11919393 DOI: 10.1159/000046641] [Citation(s) in RCA: 106] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Acquired reciprocal chromosomal translocations that involve chromosome bands 5q31-33 are associated with a significant minority of patients with BCR-ABL-negative chronic myeloid leukemias. The most common abnormality is the t(5;12)(q33;p13), which fuses the ETV6/TEL gene to the platelet-derived growth factor receptor-beta (PDGFRB), a receptor tyrosine kinase that maps to 5q33. PDGFRB is disrupted by other translocations and to date four additional partner genes (H4, HIP1, CEV14 and Rab5) have been reported. Clinically, most patients present with a myeloproliferative disorder (MPD) with eosinophilia, eosinophilic leukemia or chronic myelomonocytic leukemia and thus fall into the broader category of myeloproliferative disorders/myelodysplastic syndromes (MPD/MDS). With the advent of targeted signal transduction therapy, patients with rearrangement of PDGFRB might be better classified as a distinct subgroup of MPD/MDS.
Collapse
Affiliation(s)
- E Joanna Steer
- Wessex Regional Genetics Laboratory, Salisbury District Hospital, UK
| | | |
Collapse
|
55
|
Abstract
Asthma is the most common chronic childhood disease in developed nations and is a complex disease that has high social and economic costs. Asthma and its associated intermediate phenotypes are under a substantial degree of genetic control. Identifying the genes underlying asthma offers a means of better understanding its pathogenesis, with the promise of improving preventive strategies, diagnostic tools, and therapies. A number of chromosomal regions containing genes influencing asthma and atopy have been identified consistently by different groups, and a role for several candidate genes has been established.
Collapse
|
56
|
Sengler C, Lau S, Wahn U, Nickel R. Interactions between genes and environmental factors in asthma and atopy: new developments. Respir Res 2002; 3:7. [PMID: 11806842 PMCID: PMC64818 DOI: 10.1186/rr179] [Citation(s) in RCA: 85] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2001] [Revised: 07/10/2001] [Accepted: 07/27/2001] [Indexed: 01/06/2023] Open
Abstract
Asthma and associated phenotypes are complex traits most probably caused by an interaction of multiple disease susceptibility genes and environmental factors. Major achievements have occurred in identifying chromosomal regions and polymorphisms in candidate genes linked to or associated with asthma, atopic dermatitis, IgE levels and response to asthma therapy. The aims of this review are to explain the methodology of genetic studies of multifactorial diseases, to summarize chromosomal regions and polymorphisms in candidate genes linked to or associated with asthma and associated traits, to list genetic alterations that may alter response to asthma therapy, and to outline genetic factors that may render individuals more susceptible to asthma and atopy due to environmental changes.
Collapse
Affiliation(s)
- Claudia Sengler
- Department of Pediatric Pneumology and Immunology, Charité, Humboldt University Berlin, Berlin, Germany
| | - Susanne Lau
- Department of Pediatric Pneumology and Immunology, Charité, Humboldt University Berlin, Berlin, Germany
| | - Ulrich Wahn
- Department of Pediatric Pneumology and Immunology, Charité, Humboldt University Berlin, Berlin, Germany
| | - Renate Nickel
- Department of Pediatric Pneumology and Immunology, Charité, Humboldt University Berlin, Berlin, Germany
| |
Collapse
|
57
|
Holberg CJ, Halonen M, Solomon S, Graves PE, Baldini M, Erickson RP, Martinez FD. Factor analysis of asthma and atopy traits shows 2 major components, one of which is linked to markers on chromosome 5q. J Allergy Clin Immunol 2001; 108:772-80. [PMID: 11692103 DOI: 10.1067/mai.2001.119158] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
BACKGROUND A variety of definitions of asthma and atopy traits have been used in genetic studies. The variables used may be correlated, increasing the likelihood of type I error. OBJECTIVE We sought to clarify and quantify phenotypes that may be characterized by related traits. Principal components and factor analysis were applied to the correlation matrix of asthma and atopy traits before linkage analysis. METHODS Factor analysis was performed on 468 Hispanic and non-Hispanic white children enrolled in the Tucson Children's Respiratory Study, with complete information on 24 items, including skin test response to 7 allergens, total serum IgE levels, presence or absence of asthma attacks, wheezing episodes, hay fever, and cough. Factor score coefficients were then applied to all siblings (n = 877), and quantitative factor scores were derived. Single-point and multipoint nonparametric sib-pair analyses were performed to assess linkage to markers on chromosome 5q31-33. Analyses were also performed for individual items. RESULTS Two main factors were identified: Factor I had high loadings on atopic items, including skin test responses, IgE, and hay fever, and Factor II had high loadings that included asthma diagnosis, wheezing, cough, and Alternaria species skin test response. Factors I and II were correlated at an r value of 0.19. For the quantitative factor scores, significant single-point linkage (P < .0001) was demonstrated only for atopic Factor I, and a peak multipoint LOD score of 2.7 was seen for marker D5S479. Multipoint LOD scores for individual items were 1.1 or less. CONCLUSION These analyses suggest evidence for a locus or loci mapping to chromosome 5q31-33 associated with this composite atopic phenotype.
Collapse
Affiliation(s)
- C J Holberg
- Arizona Respiratory Center and the Department of Pediatrics, University of Arizona Health Sciences Center, Tucson 85724, USA
| | | | | | | | | | | | | |
Collapse
|
58
|
Rioux JD, Daly MJ, Silverberg MS, Lindblad K, Steinhart H, Cohen Z, Delmonte T, Kocher K, Miller K, Guschwan S, Kulbokas EJ, O'Leary S, Winchester E, Dewar K, Green T, Stone V, Chow C, Cohen A, Langelier D, Lapointe G, Gaudet D, Faith J, Branco N, Bull SB, McLeod RS, Griffiths AM, Bitton A, Greenberg GR, Lander ES, Siminovitch KA, Hudson TJ. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet 2001; 29:223-8. [PMID: 11586304 DOI: 10.1038/ng1001-223] [Citation(s) in RCA: 543] [Impact Index Per Article: 22.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Linkage disequilibrium (LD) mapping provides a powerful method for fine-structure localization of rare disease genes, but has not yet been widely applied to common disease. We sought to design a systematic approach for LD mapping and apply it to the localization of a gene (IBD5) conferring susceptibility to Crohn disease. The key issues are: (i) to detect a significant LD signal (ii) to rigorously bound the critical region and (iii) to identify the causal genetic variant within this region. We previously mapped the IBD5 locus to a large region spanning 18 cM of chromosome 5q31 (P<10(-4)). Using dense genetic maps of microsatellite markers and single-nucleotide polymorphisms (SNPs) across the entire region, we found strong evidence of LD. We bound the region to a common haplotype spanning 250 kb that shows strong association with the disease (P< 2 x 10(-7)) and contains the cytokine gene cluster. This finding provides overwhelming evidence that a specific common haplotype of the cytokine region in 5q31 confers susceptibility to Crohn disease. However, genetic evidence alone is not sufficient to identify the causal mutation within this region, as strong LD across the region results in multiple SNPs having equivalent genetic evidence-each consistent with the expected properties of the IBD5 locus. These results have important implications for Crohn disease in particular and LD mapping in general.
Collapse
Affiliation(s)
- J D Rioux
- Whitehead Institute/Massachusetts Institute of Technology, Center for Genome Research, Cambridge, Massachusetts, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
59
|
Kauppi P, Lindblad-Toh K, Sevon P, Toivonen HT, Rioux JD, Villapakkam A, Laitinen LA, Hudson TJ, Kere J, Laitinen T. A second-generation association study of the 5q31 cytokine gene cluster and the interleukin-4 receptor in asthma. Genomics 2001; 77:35-42. [PMID: 11543630 DOI: 10.1006/geno.2001.6613] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
We have analyzed a dense set of single-nucleotide polymorphisms (SNPs) and microsatellites spanning the T-helper cytokine gene cluster (interleukins 3, 4, 5, 9, and 13, interferon regulatory factor-1, colony-stimulating factor-2, and T-cell transcription factor-7) on 5q31 and the gene encoding the interleukin-4 receptor (IL4R) on 16p12 among Finnish families with asthma. As shown by haplotype pattern mining analysis, the number of disease-associated haplotype patterns differed from that expected for the 129Q allele polymorphism in IL13 for high serum total immunoglobulin (Ig) E levels, but not for asthma. The same SNP also yielded the best haplotype associations. For IL4R, asthma-associated haplotype patterns, most spanning the S411L polymorphism, showed suggestive association. However, these haplotypes consisted of the major alleles for the intracellular part of the receptor and were very common among both patients and controls. The minor alleles 503P and 576R have been reported to be associated with decreased serum IgE levels and changes in the biological activity of the protein, especially when inherited together. In the Finnish population, these two polymorphisms segregated in strong linkage disequilibrium. Our data support previous findings regarding L4R, indicating that 503P and 576R may act as minor protecting alleles for IgE-mediated disorders.
Collapse
Affiliation(s)
- P Kauppi
- Department of Medicine, Helsinki University Central Hospital, Helsinki, FI-00290, Finland
| | | | | | | | | | | | | | | | | | | |
Collapse
|
60
|
Cookson WO. The genetics of atopic dermatitis: strategies, candidate genes, and genome screens. J Am Acad Dermatol 2001; 45:S7-9. [PMID: 11423863 DOI: 10.1067/mjd.2001.117026] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- W O Cookson
- Oxford University, Wellcome Trust Centre for Human Genetics, United Kingdom.
| |
Collapse
|
61
|
Goobie S, Popovic M, Morrison J, Ellis L, Ginzberg H, Boocock GRB, Ehtesham N, Bétard C, Brewer CG, Roslin NM, Hudson TJ, Morgan K, Fujiwara TM, Durie PR, Rommens JM. Shwachman-Diamond syndrome with exocrine pancreatic dysfunction and bone marrow failure maps to the centromeric region of chromosome 7. Am J Hum Genet 2001; 68:1048-54. [PMID: 11254457 PMCID: PMC1275624 DOI: 10.1086/319505] [Citation(s) in RCA: 88] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2000] [Accepted: 01/18/2001] [Indexed: 11/03/2022] Open
Abstract
Shwachman-Diamond syndrome (SDS) is an autosomal recessive disorder characterized by exocrine pancreatic insufficiency and hematologic and skeletal abnormalities. A genomewide scan of families with SDS was terminated at approximately 50% completion, with the identification of chromosome 7 markers that showed linkage with the disease. Finer mapping revealed significant linkage across a broad interval that included the centromere. The maximum two-point LOD score was 8.7, with D7S473, at a recombination fraction of 0. The maximum multipoint LOD score was 10, in the interval between D7S499 and D7S482 (5.4 cM on the female map and 0 cM on the male map), a region delimited by recombinant events detected in affected children. Evidence from all 15 of the multiplex families analyzed provided support for the linkage, consistent with a single locus for SDS. However, the presence of several different mutations is suggested by the heterogeneity of disease-associated haplotypes in the candidate region.
Collapse
Affiliation(s)
- Sharan Goobie
- Programs in Genetics and Genomic Biology and Integrative Biology, Research Institute, and Division of Gastroenterology and Nutrition, The Hospital for Sick Children, and Departments of Molecular and Medical Genetics and Paediatrics, University of Toronto, Toronto; and Montreal Genome Centre, McGill University Health Centre Research Institute, and Departments of Human Genetics and Medicine, McGill University, Montreal
| | - Maja Popovic
- Programs in Genetics and Genomic Biology and Integrative Biology, Research Institute, and Division of Gastroenterology and Nutrition, The Hospital for Sick Children, and Departments of Molecular and Medical Genetics and Paediatrics, University of Toronto, Toronto; and Montreal Genome Centre, McGill University Health Centre Research Institute, and Departments of Human Genetics and Medicine, McGill University, Montreal
| | - Jodi Morrison
- Programs in Genetics and Genomic Biology and Integrative Biology, Research Institute, and Division of Gastroenterology and Nutrition, The Hospital for Sick Children, and Departments of Molecular and Medical Genetics and Paediatrics, University of Toronto, Toronto; and Montreal Genome Centre, McGill University Health Centre Research Institute, and Departments of Human Genetics and Medicine, McGill University, Montreal
| | - Lynda Ellis
- Programs in Genetics and Genomic Biology and Integrative Biology, Research Institute, and Division of Gastroenterology and Nutrition, The Hospital for Sick Children, and Departments of Molecular and Medical Genetics and Paediatrics, University of Toronto, Toronto; and Montreal Genome Centre, McGill University Health Centre Research Institute, and Departments of Human Genetics and Medicine, McGill University, Montreal
| | - Hedy Ginzberg
- Programs in Genetics and Genomic Biology and Integrative Biology, Research Institute, and Division of Gastroenterology and Nutrition, The Hospital for Sick Children, and Departments of Molecular and Medical Genetics and Paediatrics, University of Toronto, Toronto; and Montreal Genome Centre, McGill University Health Centre Research Institute, and Departments of Human Genetics and Medicine, McGill University, Montreal
| | - Graeme R. B. Boocock
- Programs in Genetics and Genomic Biology and Integrative Biology, Research Institute, and Division of Gastroenterology and Nutrition, The Hospital for Sick Children, and Departments of Molecular and Medical Genetics and Paediatrics, University of Toronto, Toronto; and Montreal Genome Centre, McGill University Health Centre Research Institute, and Departments of Human Genetics and Medicine, McGill University, Montreal
| | - Nadia Ehtesham
- Programs in Genetics and Genomic Biology and Integrative Biology, Research Institute, and Division of Gastroenterology and Nutrition, The Hospital for Sick Children, and Departments of Molecular and Medical Genetics and Paediatrics, University of Toronto, Toronto; and Montreal Genome Centre, McGill University Health Centre Research Institute, and Departments of Human Genetics and Medicine, McGill University, Montreal
| | - Christine Bétard
- Programs in Genetics and Genomic Biology and Integrative Biology, Research Institute, and Division of Gastroenterology and Nutrition, The Hospital for Sick Children, and Departments of Molecular and Medical Genetics and Paediatrics, University of Toronto, Toronto; and Montreal Genome Centre, McGill University Health Centre Research Institute, and Departments of Human Genetics and Medicine, McGill University, Montreal
| | - Carl G. Brewer
- Programs in Genetics and Genomic Biology and Integrative Biology, Research Institute, and Division of Gastroenterology and Nutrition, The Hospital for Sick Children, and Departments of Molecular and Medical Genetics and Paediatrics, University of Toronto, Toronto; and Montreal Genome Centre, McGill University Health Centre Research Institute, and Departments of Human Genetics and Medicine, McGill University, Montreal
| | - Nicole M. Roslin
- Programs in Genetics and Genomic Biology and Integrative Biology, Research Institute, and Division of Gastroenterology and Nutrition, The Hospital for Sick Children, and Departments of Molecular and Medical Genetics and Paediatrics, University of Toronto, Toronto; and Montreal Genome Centre, McGill University Health Centre Research Institute, and Departments of Human Genetics and Medicine, McGill University, Montreal
| | - Thomas J. Hudson
- Programs in Genetics and Genomic Biology and Integrative Biology, Research Institute, and Division of Gastroenterology and Nutrition, The Hospital for Sick Children, and Departments of Molecular and Medical Genetics and Paediatrics, University of Toronto, Toronto; and Montreal Genome Centre, McGill University Health Centre Research Institute, and Departments of Human Genetics and Medicine, McGill University, Montreal
| | - Kenneth Morgan
- Programs in Genetics and Genomic Biology and Integrative Biology, Research Institute, and Division of Gastroenterology and Nutrition, The Hospital for Sick Children, and Departments of Molecular and Medical Genetics and Paediatrics, University of Toronto, Toronto; and Montreal Genome Centre, McGill University Health Centre Research Institute, and Departments of Human Genetics and Medicine, McGill University, Montreal
| | - T. Mary Fujiwara
- Programs in Genetics and Genomic Biology and Integrative Biology, Research Institute, and Division of Gastroenterology and Nutrition, The Hospital for Sick Children, and Departments of Molecular and Medical Genetics and Paediatrics, University of Toronto, Toronto; and Montreal Genome Centre, McGill University Health Centre Research Institute, and Departments of Human Genetics and Medicine, McGill University, Montreal
| | - Peter R. Durie
- Programs in Genetics and Genomic Biology and Integrative Biology, Research Institute, and Division of Gastroenterology and Nutrition, The Hospital for Sick Children, and Departments of Molecular and Medical Genetics and Paediatrics, University of Toronto, Toronto; and Montreal Genome Centre, McGill University Health Centre Research Institute, and Departments of Human Genetics and Medicine, McGill University, Montreal
| | - Johanna M. Rommens
- Programs in Genetics and Genomic Biology and Integrative Biology, Research Institute, and Division of Gastroenterology and Nutrition, The Hospital for Sick Children, and Departments of Molecular and Medical Genetics and Paediatrics, University of Toronto, Toronto; and Montreal Genome Centre, McGill University Health Centre Research Institute, and Departments of Human Genetics and Medicine, McGill University, Montreal
| |
Collapse
|
62
|
Lee N, Daly MJ, Delmonte T, Lander ES, Xu F, Hudson TJ, Mitchell GA, Morin CC, Robinson BH, Rioux JD. A genomewide linkage-disequilibrium scan localizes the Saguenay-Lac-Saint-Jean cytochrome oxidase deficiency to 2p16. Am J Hum Genet 2001; 68:397-409. [PMID: 11156535 PMCID: PMC1235273 DOI: 10.1086/318197] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2000] [Accepted: 11/30/2000] [Indexed: 11/03/2022] Open
Abstract
Leigh syndrome (LS) affects 1/40,000 newborn infants in the worldwide population and is characterized by the presence of developmental delay and lactic acidosis and by a mean life expectancy variously estimated at 3-5 years. Saguenay-Lac-Saint-Jean (SLSJ) cytochrome oxidase (COX) deficiency (LS French-Canadian type [LSFC] [MIM 220111]), an autosomal recessive form of congenital lactic acidosis, presents with developmental delay and hypotonia. It is an LS variant that is found in a geographically isolated region of Quebec and that occurs in 1/2,178 live births. Patients with LSFC show a phenotype similar to that of patients with LS, but the two groups differ in clinical presentation. We studied DNA samples from 14 patients with LSFC and from their parents, representing a total of 13 families. Because of founder effects in the SLSJ region, considerable linkage disequilibrium (LD) was expected to surround the LSFC mutation. We therefore performed a genomewide screen for LD, using 290 autosomal microsatellite markers. A single marker, D2S1356, located on 2p16, showed significant (P < 10(-5)) genomewide LD. Using high-resolution genetic mapping with additional markers and four additional families with LSFC, we were able to identify a common ancestral haplotype and to limit the critical region to approximately 2 cM between D2S119 and D2S2174. COX7AR, a gene encoding a COX7a-related protein, had previously been mapped to this region. We determined the genomic structure and resequenced this gene in patients with LSFC and in controls but found no functional mutations. Although the LSFC gene remains to be elucidated, the present study demonstrates the feasibility of using a genomewide LD strategy to localize the critical region for a rare genetic disease in a founder population.
Collapse
Affiliation(s)
- Nana Lee
- Metabolism Research Programme, Research Institute, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Montréal Genome Centre, McGill University Health Centre Research Institute, and Service de Génétique Médicale, Hôpital Sainte-Justine, Montréal; and Department of Pediatrics and Research Clinic Unit, Chicoutimi Hospital, Chicoutimi, Québec
| | - Mark J. Daly
- Metabolism Research Programme, Research Institute, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Montréal Genome Centre, McGill University Health Centre Research Institute, and Service de Génétique Médicale, Hôpital Sainte-Justine, Montréal; and Department of Pediatrics and Research Clinic Unit, Chicoutimi Hospital, Chicoutimi, Québec
| | - Terrye Delmonte
- Metabolism Research Programme, Research Institute, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Montréal Genome Centre, McGill University Health Centre Research Institute, and Service de Génétique Médicale, Hôpital Sainte-Justine, Montréal; and Department of Pediatrics and Research Clinic Unit, Chicoutimi Hospital, Chicoutimi, Québec
| | - Eric S. Lander
- Metabolism Research Programme, Research Institute, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Montréal Genome Centre, McGill University Health Centre Research Institute, and Service de Génétique Médicale, Hôpital Sainte-Justine, Montréal; and Department of Pediatrics and Research Clinic Unit, Chicoutimi Hospital, Chicoutimi, Québec
| | - Fenghao Xu
- Metabolism Research Programme, Research Institute, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Montréal Genome Centre, McGill University Health Centre Research Institute, and Service de Génétique Médicale, Hôpital Sainte-Justine, Montréal; and Department of Pediatrics and Research Clinic Unit, Chicoutimi Hospital, Chicoutimi, Québec
| | - Thomas J. Hudson
- Metabolism Research Programme, Research Institute, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Montréal Genome Centre, McGill University Health Centre Research Institute, and Service de Génétique Médicale, Hôpital Sainte-Justine, Montréal; and Department of Pediatrics and Research Clinic Unit, Chicoutimi Hospital, Chicoutimi, Québec
| | - Grant A. Mitchell
- Metabolism Research Programme, Research Institute, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Montréal Genome Centre, McGill University Health Centre Research Institute, and Service de Génétique Médicale, Hôpital Sainte-Justine, Montréal; and Department of Pediatrics and Research Clinic Unit, Chicoutimi Hospital, Chicoutimi, Québec
| | - Charles C. Morin
- Metabolism Research Programme, Research Institute, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Montréal Genome Centre, McGill University Health Centre Research Institute, and Service de Génétique Médicale, Hôpital Sainte-Justine, Montréal; and Department of Pediatrics and Research Clinic Unit, Chicoutimi Hospital, Chicoutimi, Québec
| | - Brian H. Robinson
- Metabolism Research Programme, Research Institute, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Montréal Genome Centre, McGill University Health Centre Research Institute, and Service de Génétique Médicale, Hôpital Sainte-Justine, Montréal; and Department of Pediatrics and Research Clinic Unit, Chicoutimi Hospital, Chicoutimi, Québec
| | - John D. Rioux
- Metabolism Research Programme, Research Institute, Hospital for Sick Children, and Departments of Biochemistry and Paediatrics, University of Toronto, Toronto; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Montréal Genome Centre, McGill University Health Centre Research Institute, and Service de Génétique Médicale, Hôpital Sainte-Justine, Montréal; and Department of Pediatrics and Research Clinic Unit, Chicoutimi Hospital, Chicoutimi, Québec
| |
Collapse
|
63
|
Pajukanta P, Cargill M, Viitanen L, Nuotio I, Kareinen A, Perola M, Terwilliger JD, Kempas E, Daly M, Lilja H, Rioux JD, Brettin T, Viikari JSA, Rönnemaa T, Laakso M, Lander ES, Peltonen L. Two loci on chromosomes 2 and X for premature coronary heart disease identified in early- and late-settlement populations of Finland. Am J Hum Genet 2000; 67:1481-93. [PMID: 11078477 PMCID: PMC1287925 DOI: 10.1086/316902] [Citation(s) in RCA: 126] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2000] [Accepted: 10/09/2000] [Indexed: 12/15/2022] Open
Abstract
Coronary heart disease (CHD) is a complex disorder constituting a major health problem in Western societies. To assess the genetic background of CHD, we performed a genomewide linkage scan in two study samples from the genetically isolated population of Finland. An initial study sample consisted of family material from the northeastern part of Finland, settled by a small number of founders approximately 300 years ago. A second study sample originated from the southwestern region of Finland, settled approximately 2,000 years ago. Families were ascertained through probands exhibiting premature CHD, defined as >50% stenosis of at least two coronary arteries at a young age, as verified by coronary angiography. Both study samples and the pooled data set provided evidence for linkage in two chromosomal regions. A region on chromosome 2q21.1-22 yielded two-point LOD scores of 3.2, 1.9, and 3.7, in the affected sib-pair (ASP) analyses of the northeastern, southwestern, and pooled study samples. The corresponding multipoint maximum-likelihood scores (MLSs) for these three study samples were 2.4, 1.3, and 3.0. In addition, a region on chromosome Xq23-26 resulted in two-point LOD scores of 1.9, 3.5, and 2.9 and in multipoint MLSs of 3.4, 3.1, and 2.5, respectively. In conclusion, this study identifies two loci likely to contribute to premature CHD: one on chromosome 2q21.1-22 and another on chromosome Xq23-26.
Collapse
Affiliation(s)
- Päivi Pajukanta
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - Michele Cargill
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - Laura Viitanen
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - Ilpo Nuotio
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - Anu Kareinen
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - Markus Perola
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - Joseph D. Terwilliger
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - Elli Kempas
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - Mark Daly
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - Heidi Lilja
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - John D. Rioux
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - Thomas Brettin
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - Jorma S. A. Viikari
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - Tapani Rönnemaa
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - Markku Laakso
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - Eric S. Lander
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| | - Leena Peltonen
- Department of Human Molecular Genetics, National Public Health Institute, Helsinki; Department of Human Genetics, Gonda Neuroscience and Genetics Research Center, University of California Los Angeles, Los Angeles; Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA; Department of Medicine, University of Kuopio, Kuopio, Finland; Department of Medicine, University of Turku, Turku, Finland; and Department of Psychiatry and Columbia Genome Center, Columbia University, New York
| |
Collapse
|
64
|
Lonjou C, Barnes K, Chen H, Cookson WO, Deichmann KA, Hall IP, Holloway JW, Laitinen T, Palmer LJ, Wjst M, Morton NE. A first trial of retrospective collaboration for positional cloning in complex inheritance: assay of the cytokine region on chromosome 5 by the consortium on asthma genetics (COAG). Proc Natl Acad Sci U S A 2000; 97:10942-7. [PMID: 11005866 PMCID: PMC27128 DOI: 10.1073/pnas.97.20.10942] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/03/2000] [Indexed: 01/22/2023] Open
Abstract
The central problem of complex inheritance is to map oligogenes for disease susceptibility, integrating linkage and association over samples that differ in several ways. Combination of evidence over multiple samples with 1,037 families supports loci contributing to asthma susceptibility in the cytokine region on 5q [maximum logarithm of odds (lod) = 2.61 near IL-4], but no evidence for atopy. The principal problems with retrospective collaboration on linkage appear to have been solved, providing far more information than a single study. A multipoint lod table evaluated at commonly agreed reference loci is required for both collaboration and metaanalysis, but variations in ascertainment, pedigree structure, phenotype definition, and marker selection are tolerated. These methods are invariant with statistical methods that increase the power of lods and are applicable to all diseases, motivating collaboration rather than competition. In contrast to linkage, positional cloning by allelic association has yet to be extended to multiple samples, a prerequisite for efficient combination with linkage and the greatest current challenge to genetic epidemiology.
Collapse
Affiliation(s)
- C Lonjou
- Human Genetics Research Division, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
65
|
|
66
|
Abstract
Asthma is the most common chronic childhood disease in developed nations, and it is a complex disease that has high social and economic costs. Asthma and its associated intermediate phenotypes are under a substantial degree of genetic control. The genetic aetiology of asthma offers a means of better understanding its pathogenesis and, thus, improving preventive strategies, diagnostic tools, and therapies. Considerable effort and expense have been expended in attempts to detect genetic loci contributing to asthma susceptibility, and extensive candidate gene studies and a number of whole-genome screens have been undertaken. This article reviews the current state of knowledge of the genetics of asthma, with a focus on genomic approaches to understanding allergic diseases.
Collapse
Affiliation(s)
- L J Palmer
- Channing Laboratory, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
| | | |
Collapse
|
67
|
Mansur AH, Christie G, Turner A, Bishop DT, Markham AF, Helms P, Morrison JF. Lack of linkage between chromosome 5q23-33 markers and IgE/bronchial hyperreactivity in 67 Scottish families. Clin Exp Allergy 2000; 30:954-61. [PMID: 10848917 DOI: 10.1046/j.1365-2222.2000.00855.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
BACKGROUND Raised serum immunoglobulin E (IgE) and bronchial hyperreactivity (BHR) are risk factors for the expression of the asthma phenotype. Previous studies have reported evidence for linkage between these traits and markers on the 5q23-33 cytokine gene cluster. OBJECTIVE To test for linkage between total serum IgE/BHR and microsatellite markers which map to the 5q23-33 region in an ethnically distinct cohort of families from Aberdeen, Scotland. METHODS We performed a linkage study between five polymorphic markers (spanning the chromosome 5q23-33 region) and total serum IgE and BHR traits. A cohort of 67 families, who were recruited originally to study the natural history of wheeze, were clinically characterized and genotyped for D5S404, IL4, IRF-1, IL9, D5S436 markers. Linkage analyses were performed using the nonparametric Haseman-Elston algorithm for the quantitative trait log IgE, and the nonparametric LOD score (NPL-score) of the GENEHUNTER package for the qualitative traits serum IgE and BHR. RESULTS The results of the nonparametric linkage analysis using either the Haseman-Elston algorithm or NPL-score were consistent and showed no evidence for linkage with IgE. There was also no evidence for linkage between the BHR traits (at cut-off values of PD20FEV1 < 8 mmol and 16 mmol) and any of the tested five microsatellite markers. CONCLUSIONS This study presents evidence against the presence of a gene with a major effect on total serum IgE or BHR in the 5q23-33 region, in this ethnic group.
Collapse
Affiliation(s)
- A H Mansur
- Molecular Medicine Unit, Clinical Sciences Building, St. James's University Hospital, Leeds, LS9 7TF, UK
| | | | | | | | | | | | | |
Collapse
|
68
|
Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, McLeod RS, Griffiths AM, Green T, Brettin TS, Stone V, Bull SB, Bitton A, Williams CN, Greenberg GR, Cohen Z, Lander ES, Hudson TJ, Siminovitch KA. Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. Am J Hum Genet 2000; 66:1863-70. [PMID: 10777714 PMCID: PMC1378042 DOI: 10.1086/302913] [Citation(s) in RCA: 361] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2000] [Accepted: 03/30/2000] [Indexed: 11/03/2022] Open
Abstract
The chronic inflammatory bowel diseases (IBDs)-Crohn disease (CD) and ulcerative colitis (UC)-are idiopathic, inflammatory disorders of the gastrointestinal tract. These conditions have a peak incidence in early adulthood and a combined prevalence of approximately 100-200/100,000. Although the etiology of IBD is multifactorial, a significant genetic contribution to disease susceptibility is implied by epidemiological data revealing a sibling risk of approximately 35-fold for CD and approximately 15-fold for UC. To elucidate the genetic basis for these disorders, we undertook a genomewide scan in 158 Canadian sib-pair families and identified three regions of suggestive linkage (3p, 5q31-33, and 6p) and one region of significant linkage to 19p13 (LOD score 4.6). Higher-density mapping in the 5q31-q33 region revealed a locus of genomewide significance (LOD score 3.9) that contributes to CD susceptibility in families with early-onset disease. Both of these genomic regions contain numerous genes that are important to the immune and inflammatory systems and that provide good targets for future candidate-gene studies.
Collapse
Affiliation(s)
- J D Rioux
- Whitehead Institute/Massachusetts Institute of Technology, Center for Genome Research, Cambridge, MA 02139, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
69
|
Gaudet D, Arsenault S, Pérusse L, Vohl MC, St-Pierre J, Bergeron J, Després JP, Dewar K, Daly MJ, Hudson T, Rioux JD. Glycerol as a correlate of impaired glucose tolerance: dissection of a complex system by use of a simple genetic trait. Am J Hum Genet 2000; 66:1558-68. [PMID: 10736265 PMCID: PMC1378005 DOI: 10.1086/302903] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/1999] [Accepted: 02/09/2000] [Indexed: 11/03/2022] Open
Abstract
Glycerol kinase (GK) represents the primary entry of glycerol into glucose and triglyceride metabolism. Impaired glucose tolerance (IGT) and hypertriglyceridemia are associated with an increased risk of diabetes mellitus and cardiovascular disease. The relationship between glycerol and the risk of IGT, however, is poorly understood. We therefore undertook the study of fasting plasma glycerol levels in a cohort of 1,056 unrelated men and women of French-Canadian descent. Family screening in the initial cohort identified 18 men from five families with severe hyperglycerolemia (values above 2.0 mmol/liter) and demonstrated an X-linked pattern of inheritance. Linkage analysis of the data from 12 microsatellite markers surrounding the Xp21.3 GK gene resulted in a peak LOD score of 3.46, centered around marker DXS8039. In addition, since all of the families originated in a population with a proven founder effect-the Saguenay Lac-St.-Jean region of Quebec-a common disease haplotype was sought. Indeed, a six-marker haplotype extending over a region of 5.5 cM was observed in all families. Resequencing of the GK gene in family members led to the discovery of a N288D missense mutation in exon 10, which resulted in the substitution of a highly conserved asparagine residue by a negatively charged aspartic acid. Although patients with the N288D mutation suffered from severe hyperglycerolemia, they were apparently otherwise healthy. The phenotypic analysis of the family members, however, showed that glycerol levels correlated with impaired glucose metabolism and body-fat distribution. We subsequently noted a substantial variation in glycerolemia in subjects of the initial cohort with normal plasma glycerol levels and demonstrated that this variance showed significant family resemblance. These results suggest a potentially important genetic connection between fasting glycerolemia and glucose homeostasis, not only in this X-linked deficiency but, potentially, in individuals within the "normal" range of plasma glycerol concentrations.
Collapse
Affiliation(s)
- D Gaudet
- Lipid Research Group, Chicoutimi Hospital, Chicoutimi, and Lipid Research Center, Laval University, Quebec, Canada. . ca
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
70
|
Graves PE, Kabesch M, Halonen M, Holberg CJ, Baldini M, Fritzsch C, Weiland SK, Erickson RP, von Mutius E, Martinez FD. A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. J Allergy Clin Immunol 2000; 105:506-13. [PMID: 10719301 DOI: 10.1067/mai.2000.104940] [Citation(s) in RCA: 289] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
BACKGROUND Increased levels of total serum IgE are a strong risk factor for the development of asthma. IgE is also involved in host defenses against parasites and fungi. Linkage of total serum IgE with markers located close to the 3 Mb cluster of cytokine genes in chromosome 5q31 has been reported. IL-4 or IL-13 are regarded as essential for IgE synthesis. OBJECTIVE We tested whether polymorphisms in the IL-13 gene might explain the linkage between chromosome 5q31 and total serum IgE levels. METHODS We used denaturing HPLC to detect polymorphisms in overlapping PCR fragments of the IL-13 gene including promoter and 3' untranslated regions. After sequencing was performed to identify the locations of the polymorphisms, PCR and primer-induced restriction site assays were used to genotype subjects in 3 unselected populations. RESULTS We report here 7 polymorphisms (6 novel) in IL-13. Four of these polymorphisms are tightly linked to a variant in the terminal portion of the coding region of the gene that results in a predicted amino acid change in residue 130 (Arg130Gln). The Gln form is strongly associated (P =.000002) with increased serum IgE levels in 3 different populations comprising a total of 1399 children. Two additional polymorphisms in the promoter region of IL-13 are more loosely linked to Arg130Gln and are also less significantly associated with total serum IgE levels. CONCLUSION These data suggest that the Arg130Gln polymorphism in IL-13, or others in close linkage with it, is associated with the development of the elevated serum IgE phenotype.
Collapse
Affiliation(s)
- P E Graves
- Respiratory Sciences Center, Department of Pediatrics and the Children's Research Center, University of Arizona, Tucson, Ariz, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
71
|
Collins A, Ennis S, Tapper W, Morton N. Mapping oligogenes for atopy and asthma by meta-analysis. Genet Mol Biol 2000. [DOI: 10.1590/s1415-47572000000100001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Meta-analysis is presented for published studies on linkage or allelic association that have in common only reported significance levels. Reporting is biassed, and nonsignificance is seldom quantified. Therefore meta-analysis cannot identify oligogenes within a candidate region nor establish their significance, but it defines candidate regions well. Applied to a database on atopy and asthma, candidate regions are identified on chromosomes 6, 5, 16, 11, 12, 13, 14, 7, 20, and 10, in rank order from strongest to weakest evidence. On the other hand, there is little support for chromosomes 9, 8, 18, 1, and 15 in the same rank order. The evidence from 156 publications is reviewed for each region. With reasonable type I and II errors several thousand affected sib pairs would be required to detect a locus accounting for 1/10 of the genetic effect on asthma. Identification of regions by a genome scan for linkage and allelic association requires international collaborative studies to reach the necessary sample size, using lod-based methods that specify a weakly parametric alternative hypothesis and can be combined over studies that differ in ascertainment, phenotypes, and markers. This has become the central problem in complex inheritance.
Collapse
|
72
|
Abstract
Recent advances in our understanding of hypereosinophilia have related particularly to the definition of criteria for distinguishing between eosinophilic leukemia and the 'idiopathic' hypereosinophilic syndromes. In this article, leukemogenic mechanisms have been identified in a number of subtypes of eosinophilic leukemia, and the role of clones of T lymphocytes in the causation of otherwise unexplained eosinophilia has been further elucidated. The roles of various therapeutic modalities-including cytotoxic chemotherapy, interferon and bone marrow transplantation-in eosinophilic leukemia and in the idiopathic hypereosinophilic syndrome also have been further defined.
Collapse
Affiliation(s)
- B J Bain
- Department of Haematology, St Mary's Hospital, Campus of Imperial College School of Medicine, London, United Kingdom.
| |
Collapse
|
73
|
Conti F, Dal' Colletto GMD, Feitosa MF, Krieger H. Evidence for biological inheritance of the eosinophil response to internal parasites in southeastern Brazil. Genet Mol Biol 1999. [DOI: 10.1590/s1415-47571999000400004] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
One hundred and seventy-seven individuals belonging to 120 complete or incomplete nuclear families from Bambui, in the State of Minas Gerais, southeastern Brazil, were studied in order to examine causes of variation in the eosinophil rate among subjects infested by intestinal worms with an extra-digestive cycle. Segregation analysis without correction for skewness showed that the hypothesis of the presence of an additive major gene was consistent with the data, although a dominant, recessive, or a multifactorial hypothesis could not account properly for the observed significant familial aggregation. The most parsimonious correction for skewness showed similar results, but could not distinguish between dominant and recessive models, although co-dominance was rejected. Since these models assume that skewness was attributable to the commingling of two distributions, these results seem to agree with those for uncorrected data. These findings suggest that several genetically independent factors determine the resistance/susceptibility to helminth infestation mainly through their ability to influence the eosinophil response.
Collapse
Affiliation(s)
| | | | | | - Henrique Krieger
- Universidade de São Paulo, Brasil; Washington University School of Medicine, USA
| |
Collapse
|
74
|
Yagasaki F, Jinnai I, Yoshida S, Yokoyama Y, Matsuda A, Kusumoto S, Kobayashi H, Terasaki H, Ohyashiki K, Asou N, Murohashi I, Bessho M, Hirashima K. Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukemia with t(5;12)(q31;p13). Genes Chromosomes Cancer 1999; 26:192-202. [PMID: 10502316 DOI: 10.1002/(sici)1098-2264(199911)26:3<192::aid-gcc2>3.0.co;2-e] [Citation(s) in RCA: 61] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
We identified a novel human long fatty acyl CoA synthetase 2 gene, ACS2, as a new ETV6 fusion partner gene in a recurrent t(5;12)(q31;p13) translocation in a patient with refractory anemia with excess blasts (RAEB) with basophilia, a patient with acute myelogenous leukemia (AML) with eosinophilia, and a patient with acute eosinophilic leukemia (AEL). ACS2 is expressed in the brain and bone marrow and is highly conserved in man and rats. The resulting ETV6/ACS2 fusion transcripts showed an out-frame fusion of exon 1 of ETV6 to exon 1 of ACS2 in the AEL case, an out-frame fusion of exon 1 of ETV6 to exon 11 of ACS2 in the AML case, and a short in-frame fusion of ETV6 exon 1 to the 3' untranslated region of ACS2 in the RAEB case. Reciprocal ACS2/ETV6 transcripts were identified in two of the cases. Fluorescence in situ hybridization (FISH) analysis with ETV6 cosmids on 12p13, and BACs and P1s on 5q31, demonstrated that the 5q31 breakpoints of the AML and AEL cases involved the 5' portion of the ACS2 gene, and that the 5q31, breakpoint of the RAEB case involved the 3' portion of the ACS2 gene. None of the resulting chimeric transcripts except for the ACS2/ETV6 transcript in the RAEB case led to a fusion protein. Disruption of the second ETV6 allele by t(12;19) was detected in the AML case by FISH analysis. These observations suggest that the disruption of ETV6 and/or ACS2 may lead to the pathogenesis of hematologic malignancies with t(5;12)(q31;p13).
Collapse
MESH Headings
- Adult
- Amino Acid Sequence
- Artificial Gene Fusion
- Base Sequence
- Blotting, Northern
- Chromosome Mapping
- Chromosomes, Human, Pair 12
- Chromosomes, Human, Pair 5
- Coenzyme A Ligases/genetics
- DNA, Neoplasm/analysis
- DNA-Binding Proteins/genetics
- Exons
- Female
- Humans
- In Situ Hybridization, Fluorescence
- Leukemia, Myeloid, Acute/genetics
- Male
- Middle Aged
- Molecular Sequence Data
- Nuclear Proteins/genetics
- Phosphoproteins/genetics
- Proto-Oncogene Proteins c-ets
- RNA, Neoplasm/analysis
- Repressor Proteins
- Reverse Transcriptase Polymerase Chain Reaction
- Sequence Analysis, DNA
- Transcription Factors/genetics
- Translocation, Genetic
- ETS Translocation Variant 6 Protein
Collapse
Affiliation(s)
- F Yagasaki
- First Department of Internal Medicine, Saitama Medical School, Saitama, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
75
|
Dessein AJ, Hillaire D, Elwali NE, Marquet S, Mohamed-Ali Q, Mirghani A, Henri S, Abdelhameed AA, Saeed OK, Magzoub MM, Abel L. Severe hepatic fibrosis in Schistosoma mansoni infection is controlled by a major locus that is closely linked to the interferon-gamma receptor gene. Am J Hum Genet 1999; 65:709-21. [PMID: 10441577 PMCID: PMC1377977 DOI: 10.1086/302526] [Citation(s) in RCA: 159] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
Abstract
Lethal disease due to hepatic periportal fibrosis occurs in 2%-10% of subjects infected by Schistosoma mansoni in endemic regions such as Sudan. It is unknown why few infected individuals present with severe disease, and inherited factors may play a role in fibrosis development. Schistosoma mansoni infection levels have been shown to be controlled by a locus that maps to chromosome 5q31-q33. To investigate the genetic control of severe hepatic fibrosis (assessed by ultrasound examination) causing portal hypertension, a segregation analysis was performed in 65 Sudanese pedigrees from the same village. Results provide evidence for a codominant major gene, with.16 as the estimated allele A frequency predisposing to advanced periportal fibrosis. For AA males, AA females, and Aa males a 50% penetrance is reached after, respectively, 9, 14, and 19 years of residency in the area, whereas for other subjects the penetrance remains <.02 after 20 years of exposure. Linkage analysis performed in four candidate regions shows that this major locus maps to chromosome 6q22-q23 and that it is closely linked (multipoint LOD score 3.12) to the IFN-gammaR1 gene encoding the receptor of the strongly antifibrogenic cytokine interferon-gamma. These results show that infection levels and advanced hepatic fibrosis in human schistosomiasis are controlled by distinct loci; they suggest that polymorphisms within the IFN-gammaR1 gene could determine severe hepatic disease due to S. mansoni infection and that the IFN-gammaR1 gene is a strong candidate for the control of abnormal fibrosis observed in other diseases.
Collapse
Affiliation(s)
- A J Dessein
- INSERM U.399, Immunology and Genetics of Parasitic Diseases, Faculty of Medicine, Marseille, France.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
76
|
Rothenberg ME, Zimmermann N, Mishra A, Brandt E, Birkenberger LA, Hogan SP, Foster PS. Chemokines and chemokine receptors: their role in allergic airway disease. J Clin Immunol 1999; 19:250-65. [PMID: 10535601 DOI: 10.1023/a:1020531322556] [Citation(s) in RCA: 67] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
One of the hallmarks of allergic pulmonary disorders is the accumulation of an abnormally large number of leukocytes including eosinophils, neutrophils, lymphocytes, basophils, and macrophages in the lung. There is now substantial evidence that eosinophils, under the control of T lymphocytes, are major effector cells in the pathogenesis of asthma. Therefore, understanding the mechanisms by which eosinophils accumulate and are activated in tissues is a fundamental question very relevant to allergic diseases. Another characteristic of allergic inflammation is the activation of leukocytes resulting in the release of biologically active mediators, such as histamine from mast cells and basophils. It is now apparent that chemokines are potent leukocyte chemoattractants, cellular activating factors, histamine releasing factors, and regulators of homeostatic immunity, making them particularly important in the pathogenesis of airway inflammation in asthma. In this regard, chemokines are attractive new therapeutic targets for the treatment of allergic disease. This article focuses on recently emerging data on the importance of chemokines and their receptors in allergic airway inflammation.
Collapse
Affiliation(s)
- M E Rothenberg
- Department of Pediatrics, Children's Hospital Medical Center, Cincinnati, Ohio 45229-3039, USA.
| | | | | | | | | | | | | |
Collapse
|
77
|
Broide DH, Hoffman H, Sriramarao P. Genes that regulate eosinophilic inflammation. Am J Hum Genet 1999; 65:302-7. [PMID: 10417272 PMCID: PMC1377928 DOI: 10.1086/302520] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Affiliation(s)
- D H Broide
- Department of Medicine, University of California San Diego, La Jolla, CA 92093-0635, USA.
| | | | | |
Collapse
|